Edition:
United States

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

12.12USD
3:59pm EST
Change (% chg)

$-0.23 (-1.86%)
Prev Close
$12.35
Open
$12.29
Day's High
$12.78
Day's Low
$11.83
Volume
946,941
Avg. Vol
788,806
52-wk High
$14.47
52-wk Low
$3.30

Latest Key Developments (Source: Significant Developments)

Immunomedics announces first quarter fiscal results
Thursday, 9 Nov 2017 04:10pm EST 

Nov 9 (Reuters) - Immunomedics Inc :Immunomedics announces first quarter fiscal 2018 results and provides corporate update.Q1 loss per share $0.97.Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Immunomedics Inc - qtrly ‍total revenue was $0.7 million for both quarters ended September 30, 2017 and September 30, 2016​.  Full Article

Immunomedics to exchange about $80 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock
Friday, 15 Sep 2017 08:01am EDT 

Sept 15 (Reuters) - Immunomedics Inc :Immunomedics announces agreements to exchange approximately $80.0 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock.Immunomedics- To exchange about $80.0 mln of notes, for about 14.1 million newly issued shares of co's stock plus additional number of newly issued shares.Immunomedics- upon completion, aggregate principal amount of co's 4.75 pct Convertible Senior Notes due 2020 is to be reduced to about $20.0 mln.  Full Article

Immunomedics reports Q4 loss per share $0.48
Wednesday, 16 Aug 2017 04:00pm EDT 

Aug 16 (Reuters) - Immunomedics Inc :Immunomedics announces fiscal 2017 results and strategic developments; reiterates guidance on bla submission timeline.Q4 revenue fell 33 percent to $600,000.Q4 revenue view $2.3 million -- Thomson Reuters I/B/E/S.Q4 loss per share $0.48.Q4 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Immunomedics Inc - ‍cash, cash equivalents, and marketable securities totaled $154.9 million as of june 30, 2017​.Immunomedics Inc - ‍company expects to present final results of IMMU-132 in mtnbc that will form basis of bla submission later this year​.Immunomedics Inc - ‍believe that current financial resources are sufficient to support operations through september 2018​.  Full Article

Immunomedics, Covance enter into master services agreement
Friday, 4 Aug 2017 04:12pm EDT 

Aug 4 (Reuters) - Immunomedics Inc ::Immunomedics Inc says ‍on July 31, co and Covance Inc entered into a master services agreement - SEC filing​.Immunomedics Inc - simultaneous with execution of agreement, covance and company executed a first work order with an effective date of july 31, 2017.Immunomedics - pursuant to terms of agreement, Covance to provide clinical services for clinical study or studies to co​.Immunomedics - under work order, co engaged Covance as clinical research organization to perform services in co's phase 3 clinical trial of sacituzumab govitecan.  Full Article

Immunomedics files for offering of 34.8 mln shares of common stock by selling stockholders
Monday, 31 Jul 2017 06:13pm EDT 

July 31 (Reuters) - Immunomedics Inc :Immunomedics files for offering of 34.8 million shares of common stock by selling stockholders - sec filing.Immunomedics inc says will not receive any of proceeds from sale of common stock by the selling stockholders.  Full Article

Immunomedics files for 34.8 mln shares of co's common stock
Monday, 31 Jul 2017 06:07pm EDT 

July 31 (Reuters) - Immunomedics Inc -:Files for 34.8 million shares of co's common stock by the selling stockholders - sec filing.Immunomedics Inc says will not receive any of proceeds from sale of common stock by the selling stockholders.  Full Article

Seattle Genetics reports 8.2 percent stake in Immunomedics as of June 29, 2017
Friday, 7 Jul 2017 05:20pm EDT 

July 7 (Reuters) - Seattle Genetics Inc : :Seattle genetics inc reports a 8.2 percent stake in immunomedics inc as of June 29, 2017 - sec filing.Seattle Genetics- acquired common stock, warrant in connection with development, license agreement with issuer to acquire strategic interest in Immunomedics.  Full Article

Immunomedics Q3 loss per share $0.55
Wednesday, 10 May 2017 04:00pm EDT 

May 10 (Reuters) - Immunomedics Inc ::Immunomedics announces third quarter fiscal 2017 results and clinical program developments.Q3 loss per share $0.55.Q3 revenue $1.3 million.Immunomedics Inc says total costs and expenses for quarter ended March 31, 2017 were $23.4 million, compared to $15.5 million for same quarter in fiscal 2016.Immunomedics Inc says recognized a $28.3 million non-cash expense during three-month period ended March 31, 2017.  Full Article

Immunomedics announces private placement offering
Friday, 5 May 2017 08:46am EDT 

May 5 (Reuters) - Immunomedics Inc : :Immunomedics delivers business updates, announces private placement offering and outlines strategic steps to drive stockholder value.Immunomedics Inc - cfo michael garone to be named interim ceo once settlement agreement is finalized.Immunomedics Inc - board in process of considering candidates for permanent CEO.Immunomedics - has raised $125 million in gross proceeds in private placement of its series A-1 convertible preferred stock with institutional investors.Immunomedics Inc - now targeting submission of a BLA for Immu-132 for approval in MTNBC between late Q4 2017 and q1 2018.Immunomedics - to proceed with final selection of cro to launch confirmatory phase 3 study, expect first patient enrolled in late Q3 2017 for immu-132.Immunomedics Inc - Cynthia L. Sullivan will be stepping down from all director and officer positions with company.Immunomedics Inc - David M. Goldenberg, founder of company, is stepping down from all officer positions with company.Immunomedics Inc - Goldenberg will continue to serve as a director on Immunomedics' board.Immunomedics Inc - entered into a binding term sheet with Goldenberg, Sullivan, Markison and Venbio.Immunomedics Inc - Immunomedics expects to have sufficient operating funds through Q3 of 2018.Immunomedics Inc - regarding venbio action, individual defendants Goldenberg, Sullivan And Markison will be released from all claims made by Venbio.  Full Article

Seattle Genetics terminates license agreement with Immunomedics
Friday, 5 May 2017 08:00am EDT 

May 5 (Reuters) - Seattle Genetics Inc ::Seattle Genetics terminates license agreement with Immunomedics for sacituzumab govitecan (immu-132).As part of termination, Seattle Genetics will continue to hold 3.0 million shares of Immunomedics common stock.Seattle Genetics-effective upon termination of license, parties agreed to fully settle, resolve, release each other from all disputes, claims, liabilities.  Full Article

BRIEF-Immunomedics appoints Michael Pehl president and CEO

* Immunomedics appoints Michael Pehl president and chief executive officer to lead next phase of transformative growth